24 results about "Autoinflammatory disease" patented technology

Provided herein, inter alia, are novel compositions and solid forms of Compound 1 useful for the prevention and / or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplant rejection, diseases involving impairment of cartilage renewal, congenital cartilage malformations, and / or intermediates associated with IFN [alpha], interferon ("interferon disease", etc. In particular type I or type III interferon disease), diseases associated with excessive secretion of IL-12 and / or IL-23. # imgabs0 #

The present invention discloses compounds according to Formula I:wherein R1a, R1b, R1c, R2a, W1, W2, X1, X2, X3, Y, and Z are as defined herein.The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and / or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and / or IL-23, respiratory diseases, endocrine and / or metabolic diseases, cardiovascular diseases, dermatological diseases, and / or abnormal angiogenesis associated diseases by administering the compound of the invention.

The present invention provides novel compounds of Formula (I) and pharmaceutically acceptable salts, solvates, hydrates, tautomers, stereoisomers, isotopically labeled derivatives, and compositions thereof. Also provided are methods and kits involving the compounds or compositions for treating or preventing proliferative diseases in a subject, wherein the proliferative diseases include cancer, benign neoplasm, angiogenesis, inflammatory disease, autoinflammatory disease, and autoimmune disease, and the cancer includes leukemia, melanoma, multiple myeloma. Treatment of a subject having a proliferative disease with the compounds or compositions of the present invention can inhibit abnormal activity of cyclin-dependent kinase 7, thus inducing apoptosis and / or inhibiting transcription in the subject.

The present invention addresses the problem of providing a compound having an NLRP3 inflammasome activation inhibitory activity and being useful for the prevention and / or treatment of autoinflammatory diseases, autoimmune diseases and / or inflammatory diseases, or a pharmaceutically acceptable salt thereof. The solution of the present invention is a compound represented by general formula (1) or a pharmaceutically acceptable salt thereof, # imgabs0 # [wherein the symbols are as defined below. In the formula, A represents a carbon atom or the like, R1 represents a halogen atom or the like, R1'represents a hydrogen atom or the like, R1 ''represents a hydrogen atom or the like, R1' 'represents a hydrogen atom or the like, R2 represents a hydrogen atom or the like, R2'represents a hydrogen atom or the like, and R3 represents a C1-C3 alkyl group or the like.

The present invention discloses compounds according to Formula I:Wherein R1, L1, R2, L2, R3, Cy, and the subscript n are as defined herein.The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and / or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and / or diseases associated with hypersecretion of IFNα, IL12 and / or IL23 by administering the compound of the invention.

This invention discloses compounds of formula I, wherein X1, X2, and R 1 and R 2 As defined herein, this invention relates to compounds for the prevention and / or treatment of the following diseases, methods of their preparation, pharmaceutical compositions comprising them, and methods of treatment using them: inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplant rejection, diseases involving impaired cartilage turnover, congenital cartilage malformations, diseases involving impaired bone turnover, diseases associated with excessive IL-6 secretion, diseases associated with excessive secretion of TNFα, interferon, IL-12, IL-17, and / or IL-23, respiratory diseases, endocrine diseases, metabolic diseases, cardiovascular diseases, skin diseases, and / or diseases associated with abnormal angiogenesis, wherein the methods are carried out by administering the compounds of the invention.

The invention relates to the technical field of molecular biology, in particular to application of RIPK3 gene mutation as a detection target and a detection reagent. An experiment shows that an individual with heterozygote RIPK3 mutation (c.400Cgt; A, p.Gln134Lys) shows the symptom of a Still disease sample self-inflammatory disease, and a potential relation exists between the variation and immune disorder, and is characterized in that necroptosis sensitivity is increased and an inflammatory signal is amplified, so that a pro-inflammatory environment is caused. According to the invention, the relation between RIPK3 variation and the expression of the self-inflammatory disease of the Stetier disease sample is established, the understanding of people on the molecular basis of the self-inflammatory disease of the Stetier disease sample is expanded, and the importance of RIPK3 in human immune homeostasis is emphasized.

The present disclosure relates generally to adaptors, systems, and cells for the use with chimeric antigen receptors and / or synNotch receptors. Disclosed herein is a chimeric antigen receptor (CAR) system, a synthetic notch (synNotch) receptor system, and the method of use thereof in treating a disease or disorder (such as, for example, a cancer, an autoimmune disease, an autoinflammatory disease, a viral infection, a bacterial infection, or a fungal infection) in a subject. Further disclosed herein is an engineered cell comprising a chimeric antigen receptor (CAR) system and / or a synthetic notch (synNotch) receptor system.

NLRP3 PET radiotracers are provided, as are methods of using the NLRP3 PET radiotracers to image and / or diagnose diseases and conditions associated with inflammation, such as multiple sclerosis (MS), Alzheimer's disease (AD), traumatic brain injury (TBI), Parkinson's disease (PD), acute myocardial infarction (AMI), heart failure, gout, rheumatoid arthritis, COVID- 19, diabetes, macular degeneration, and autoimmune / autoinflammatory diseases.

NLRP3 PET radiotracers are provided, as are methods of using the NLRP3 PET radiotracers to image and / or diagnose diseases and conditions associated with inflammation, such as multiple sclerosis (MS), Alzheimer's disease (AD), traumatic brain injury (TBI), Parkinson's disease (PD), acute myocardial infarction (AMI), heart failure, gout, rheumatoid arthritis, COVID- 19, diabetes, macular degeneration, and autoimmune / autoinflammatory diseases.

The invention discloses a small molecular compound targeting ZBP1 and application thereof, and belongs to the technical field of biological medicine. The small molecule compound targeting ZBP1 is 9 ''-salvianolic acid B monomethyl ester, the CAS number is 1167424-31-8, experiments verify that the 9''-salvianolic acid B monomethyl ester is combined with an RHIM structural domain of ZBP1, combination of ZBP1 with RIPK1 and RIPK3 is inhibited, and therefore downstream pathway activation is inhibited, and therefore the ZBP1 targeting inhibitor is provided and used for preparing a medicine for treating diseases caused by excessive activation of ZBP1, and the application prospect is wide. Such as autoinflammatory diseases, tissue damage and chronic inflammatory diseases. A small molecule compound 9 ''-salvianolic acid B monomethyl ester capable of being combined with ZBP1 is screened from an existing small molecule compound library, the effectiveness of targeted inhibition of ZBP1 expression is proved through experiments, and a new thought is provided for treating diseases caused by excessive activation of ZBP1.

The present disclosure relates to compounds of Formula (I): and their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods of their preparation. The compounds disclosed herein are useful for inhibiting maturation of cytokines of the IL-1 family by inhibiting inflammasomes and for treating disorders in which inflammasome activity is implicated, such as inflammatory diseases, autoinflammatory diseases and autoimmune diseases and cancer.

Tri-cyclyl nitrogen-containing heterocyclic compoundsare disclosed. The compounds are inhibitors of human cGAS in interferon-producing cell types. They are thus useful as therapeutic agents for treating cGAS-related autoimmune diseases in humans.

The present invention discloses compounds according to Formula I:wherein R1, R2a, W, X1, X2, Y and Z are as defined herein.The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and / or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12 and / or IL-23, respiratory diseases, endocrine and / or metabolic diseases, cardiovascular diseases, dermatological diseases, and / or abnormal angiogenesis associated diseases by administering the compound of the invention.

Provided herein are synthetic polypeptides derived from the high mobility group box 1 (HMGB1) host protein that can disrupt bacterial biofilms and prevent the formation of neutrophil extracellular traps (NETs). Also provided herein are methods for disrupting abnormal or excessive NET formation, particularly suitable for treating high-risk populations, such as those infected with SARS-CoV-2, sepsis, autoimmune diseases (such as systemic lupus erythematosus, rheumatoid arthritis, type 1 diabetes, and small vessel vasculitis), autoinflammatory diseases (such as gout and inflammatory bowel disease), and metabolic diseases (such as type 2 diabetes and obesity).

NSIs with anti-inflammatory activity are provided, as are methods of using the NSIs to inhibit inflammation and prevent or treat diseases and conditions associated with inflammation, such as multiple sclerosis (MS), Alzheimer's disease (AD), traumatic brain injury (TBI), Parkinson's disease (PD), acute myocardial infarction (AMI), heart failure, gout, rheumatoid arthritis, COVID- 19, diabetes, macular degeneration, or an autoimmune or autoinflammatory disease.

The present invention discloses compounds according to Formula (I) wherein X1, X2, Y, R1, L1, R 2, R 3, Cy and the subscript n are as defined herein. The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and / or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplant rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6, diseases associated with hypersecretion of TNFα, interferons, IL-12, IL-17 and / or IL-23, respiratory diseases, endocrine diseases, metabolic diseases, cardiovascular diseases, dermatological diseases, and / or abnormal angiogenesis associated diseases by administering a compound of the invention.

The present invention provides novel compounds of Formula (I), (II), or (III), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and / or preventing proliferative diseases (e.g., cancers (e.g., leukemia, acute lymphoblastic leukemia, lymphoma, Burkitt's lymphoma, melanoma, multiple myeloma, breast cancer, Ewing's sarcoma, osteosarcoma, brain cancer, ovarian cancer, neuroblastoma, lung cancer, colorectal cancer), benign neoplasms, diseases associated with angiogenesis, inflammatory diseases, autoinflammatory diseases, and autoimmune diseases) in a subject. Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit the aberrant activity of a kinase, such as a cyclin-dependent kinase (CDK) (e.g., CDK7, CDK12, or CDK13), and therefore, induce cellular apoptosis and / or inhibit transcription in the subject.

Provided herein are lipid compounds of Formulae (I) and (II), and pharmaceutically acceptable salts, co-crystals, tautomers, stereoisomers, solvates, hydrates, polymorphs, isotopically labeled derivatives, prodrugs, and compositions thereof. Also provided are methods and kits involving the inventive lipid compounds, compositions, or formulations for treating and / or preventing diseases (e.g., genetic disease, proliferative disease, hematological disease, neurological disease, painful condition, psychiatric disorder, metabolic disorder, long-term medical condition, inflammatory disease, autoinflammatory disease, liver disease, lung disease, spleen disease, familial amyloid neuropathy, cardiovascular disease, viral infection, infectious disease, fibrotic condition, or autoimmune disease) in a subject, methods for synthesizing the compounds described herein, and compounds described herein synthesized by the synthetic methods described herein. The compounds are effective carriers for the delivery of an agent such as a polynucleotide (e.g., RNA) to a tissue or cell in a subject (e.g., a liver, lung, or spleen tissue / cell).

The present invention discloses compounds according to Formula I:Wherein R1, L1, R2, L2, R3, Cy, and the subscript n are as defined herein.The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and / or treatment of allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformations, and / or diseases associated with hypersecretion of IFNα, IL12 and / or IL23 by administering the compound of the invention.

The present invention provides compounds according to formula (I) wherein R1, R2, X1, X2 and X3 are as defined herein. The invention also provides methods of producing such compounds, pharmaceutical compositions comprising the same, and therapeutic methods of using the same to prevent and / or treat allergic diseases, inflammatory diseases, metabolic diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, transplant rejection, and the like by administering the compounds of the invention. Diseases involving cartilage turnover disorders, congenital cartilage malformations and / or diseases associated with hypersecretion of IFN alpha, IL-12 and / or IL-23. # imgabs0 #

The present disclosure relates generally to adaptors, systems, and cells for the use with chimeric antigen receptors and / or synNotch receptors. Disclosed herein is a chimeric antigen receptor (CAR) system, a synthetic notch (synNotch) receptor system, and the method of use thereof in treating a disease or disorder (such as, for example, a cancer, an autoimmune disease, an autoinflammatory disease, a viral infection, a bacterial infection, or a fungal infection) in a subject. Further disclosed herein is an engineered cell comprising a chimeric antigen receptor (CAR) system and / or a synthetic notch (synNotch) receptor system.

The present invention discloses compounds according to Formula I.wherein R1, R2a, W, X1, X2, Y and Z are as defined herein.The present invention relates to compounds, methods for their production, pharmaceutical compositions comprising the same, and methods of treatment using the same, for the prophylaxis and / or treatment of inflammatory diseases, autoinflammatory diseases, autoimmune diseases, proliferative diseases, fibrotic diseases, transplantation rejection, diseases involving impairment of cartilage turnover, congenital cartilage malformation, diseases involving impairment of bone turnover, diseases associated with hypersecretion of IL-6 diseases associated with hypersecretion of TNFα, interferons, IL-12 and / or IL-23, respiratory diseases, endocrine and / or metabolic diseases, cardiovascular diseases, dermatological diseases, and / or abnormal angiogenesis associated diseases by administering the compound of the invention.